Corline Biomedical
7,06
SEK
-2,49 %
CLBIO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Vær den første som følger denne virksomhed
-2,49%
-11,75%
-19,77%
-35,82%
-52,62%
-50,46%
-49,03%
-53,01%
-28,63%
www.corline.se/investors
Corline Biomedical operates in the pharmaceutical industry. The company develops with the substance heparin and has developed a portfolio of drug candidates for use in connection with organ and cell transplantation. The drug candidates are based on the same basic technology as the medical technology products. Corline Biomedical operates on the Nordic market and is headquartered in Uppsala.
Omsætning
25,03 mio.
EBIT %
-7,15 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
CLBIO
Daglig lav / høj pris
6,98 / 7,36
SEK
Markedsværdi
172,91 mio. SEK
Aktieomsætning
129,08 t SEK
Volumen
18 t
Finanskalender
Årsrapport
17.02.2025
Delårsrapport
08.05.2025
Delårsrapport
26.08.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Adam Dahlberg | 26,7 % | 26,7 % |
Eccenovo AB | 8,6 % | 8,6 % |
HealthInvest Microcap Fund AB | 8,5 % | 8,5 % |
Annika Sunnanväder | 5,8 % | 5,8 % |
M2 Asset Management AB | 4,3 % | 4,3 % |
Monika Sunnanväder | 4,0 % | 4,0 % |
Thomas Krishan | 3,7 % | 3,7 % |
Margareta Nilsson | 2,9 % | 2,9 % |
Henrik Nittmar genom bolag | 2,6 % | 2,6 % |
Thomas Olausson | 1,3 % | 1,3 % |
ViserAlle indholdstyper
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools